This book aims to provide a synthesis of current information on the mechanisms and treatment of two of the most common side effects of anti-cancer therapy - nausea and vomiting. In the past three years, considerable progress has been made towards understanding the neuropharmacology of emesis induced by anti-cancer therapy. The novel class of 5HT3-receptor antagonist anti-emetics are therefore considered in a physiological and clinical context.